Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlierts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of September, Pfizer shares jumped ~15%, rallying from roughly $23.6 to about $27.2 by Oct. 1ts2.tech. This dramatic move was largely driven by two key announcements and marked one of PFE’s strongest weekly gains in years.

NYSE:PFE · Pharmaceuticals · Stock Market
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year.
30 October 2025
·
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts.
30 October 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecastsmarketscreener.com. Sales of Keytruda, its blockbuster cancer drug, grew about 10%marketscreener.com, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales outlook while slightly raising profit guidancemarketscreener.com, a cautious stance that likely weighed on the share price.
30 October 2025
···

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly’s stock has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly. Trading volume and technical indicators suggest a consolidation phase after the recent rallyintellectia.aiintellectia.ai.
30 October 2025
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy. By Wednesday afternoon, ERNA shares were up about 48% as investors piled in on news that Ernexa is partnering with Cellipont Bioservices to scale up ERNA-101 for clinical trialsstocktwits.com. “Shares of Ernexa Therapeutics traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company,” Stocktwits reportedstocktwits.com. The stock, which had closed around $1.20 the prior day, surged to roughly $1.80 intraday, marking one of its biggest single-day gains this year.
29 October 2025
··
Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron shares recently traded around $580–$585 after a slight pullback earlier in the month investing.com. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s investing.com. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion, led by a 27% jump in Dupixent to $4.86 billion stocktitan.net. The company also won FDA approval for Libtayo in a high-risk skin cancer indication, and positive EU reviews for Libtayo and Dupixent stocktitan.net. Wall Street analysts have largely “buy” ratings on REGN: the consensus price target is about $725, implying ~25–27% upside tikr.com. The broader biotech sector has been rallying – for example, biotech ETFs are 25–34% higher since spring genengnews.com, outpacing the 24% gain in the S&P 500 over that span genengnews.com. Regeneron is still down from its 2024 highs, but recent drug wins and solid earnings are fueling renewed investor optimism.
28 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coveragecontractpharma.comgxpnews.net; GxP Newsgxpnews.netgxpnews.net; The Medicine Maker/Conexiantconexiant.comconexiant.com; GlobeNewswireglobenewswire.com; Evaluate Pharma forecastevaluate.comevaluate.com; Reutersreuters.com; TechStock² / TS2 Techts2.techts2.tech; TS2 Techts2.techts2.tech.
28 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18% from a year priorts2.tech. It languished near the bottom of its 52-week rangets2.tech as the company faced a post-pandemic hangover: revenues from its COVID-19 vaccine and pill plummeted from $37.8B in 2022 to about $12.5B in 2024ts2.tech. Wall Street projected Pfizer’s EPS would fall by more than half from 2022 to 2025ts2.tech, reflecting this “COVID cliff” in sales and ongoing patent cliffs ahead. These factors, along with drug pricing worries, weighed heavily on investor sentiment through Q3 2025.
27 October 2025
··
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal, as Wall Street cheers another biotech success story in the making. 🏥💥
26 October 2025
····
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run. The stock has surged ~28% on Oct 23 after a prior drop. Recent catalysts include completion of a 1-year Phase 3 trial showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy” with an average 12‑month target around $6.25 investing.com investing.com. By comparison, MarketBeat reports a mean $4.86 target marketbeat.com. In the broader biotech space, industry news and deals are driving rallies.
24 October 2025
···
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on recorddirectorstalkinterviews.com. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week high was about $244.8ts2.tech, and its low in the past year was ~$163.8. Notably, AbbVie surged to a record high in mid-September after the company announced a patent settlement ensuring no U.S. generics for its key drug Rinvoq until 2037reuters.com. That news – effectively a four-year extension of exclusivity – drove a 4% one-day jump in ABBV stockreuters.com. Analysts cheered the development; J.P. Morgan’s Chris Schott said the deal gives AbbVie “several more years of runway on one of its key growth drivers,” buying time to develop other drugs ahead of major mid-2030s patent lossesreuters.com. William Blair’s Matt Phipps added it could add ~$2 billion to Rinvoq’s peak sales by protecting the franchise longerreuters.com. This optimism around AbbVie’s future revenue stream helped fuel the stock’s late-summer rally.
23 October 2025
·

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Eli Lilly has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1ts2.techts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rallyts2.tech. By Oct. 23, LLY was trading near $818tradingview.com, solidly above its pre-September levels. Overall, the stock is up roughly 6% year-to-date, about matching the S&P 500 health-care indextradingview.com.
23 October 2025
··
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers – making it the first FDA-approved liquid losartan on the market ts2.tech. That morning, SCNX shares surged over 30% from the prior day’s $0.72 close, even hitting an intraday high around $1.12 before profit-taking set in ts2.tech. By mid-day Oct. 16, Reuters reported the stock had pulled back near $0.71 ts2.tech, indicating traders sold into the early pop. Still, the news established a new baseline of investor optimism.
23 October 2025
··
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion prnewswire.com. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO Greg Divis hailed the terms as “a compelling outcome for our shareholders” prnewswire.com, while Alkermes CEO Richard Pops said the deal is “a pivotal step” to accelerate Alkermes’ entry into the sleep-medicine market prnewswire.com. Avadel’s board and Alkermes’ board have approved the merger, which is expected to close in Q1 2026 pending regulatory and shareholder approval.
22 October 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on the key U.S. market to revive sales” reuters.com reuters.com. Former CEO Lars Rebien Sørensen is set to take over as chair for 2–3 years reuters.com.
22 October 2025
··
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnightmarketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the newsgurufocus.com. The shares opened around $6–7 and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past yearmarketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this micro-cap biotech.
21 October 2025
··
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

As of midday October 21, 2025, iBio’s stock trades around $0.89 per sharemarketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s closemarketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-datemarketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech sector ETF is up roughly 20% in 2025finance.yahoo.com. iBio’s modest market capitalization and thin trading volume reflect its micro-cap statusmarketbeat.comreuters.com, which can magnify price swings on news.
21 October 2025
·
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range stockanalysis.com. Trading volume is light, and the stock’s beta indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average and 200-day average suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average.
21 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion’s stock is on a rollercoaster ride this month. Early on October 20, RXRX surged ~16–18%, hitting intraday highs near $6.8benzinga.com. The rally comes after shares slid 7.9% on Friday to $5.86stockinvest.us, as traders took profits following a mid-October run-up. Broader market tailwinds helped – the Nasdaq Composite was up ~1% on Monday – and several biotech peers also soared on newsbenzinga.com. Recursion’s sharp rebound Monday recoups some losses from last week’s pullback and underscores the extreme volatility surrounding this AI-driven biotech.
20 October 2025
··
1 … 45 46 47 48 49
Follow on Google News
Add as preferred source Open in Google News